MET in non-small cell lung cancer
2 EU-approved indications in non-small cell lung cancer need a MET result: tepotinib (2nd line, advanced) and capmatinib (2nd line, advanced).
Line of therapy
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| MET mutation2 | ||||
Tabrecta | Alterations leading to METex14 skipping | Monotherapy | 2L advanced | After prior treatment with immunotherapy and/or platinum-based chemotherapy |
Tepmetko | Leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping | Monotherapy | 2L advanced | After prior treatment with immunotherapy and/or platinum-based chemotherapy |
16 approvals for NSCLC need no biomarker and apply whatever the result. All approvals for NSCLC
See also
Label wording2
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Tepotinib (Tepmetko)
TEPMETKO as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
- Capmatinib (Tabrecta)
Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.